Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | PLAT | P00750 | 2/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.31 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884596 | 0.85 | CYP3A4 (0.39) | KMT2ASCN5ASCN2AF2F10 | |
| SCHEMBL21884517 | 0.79 | HSD17B1 (0.34) | HSD17B1HSD17B2 | |
| SCHEMBL21884595 | 0.78 | FABP4 (0.39) | SCN5ASCN2AF2F10PLAU | |
| SCHEMBL21884438 | 0.76 | PPIA (0.33) | HSD17B1HSD17B2MEN1KMT2AP2RX1 | |
| SCHEMBL21884622 | 0.76 | HSD17B1 (0.38) | HSD17B1HSD17B2 | |
| SCHEMBL8668403 | 0.74 | MAPT (0.47) | KMT2ASCN5ASCN2AF2F10 | |
| SCHEMBL21884444 | 0.73 | PYGL (0.40) | MEN1KMT2APYGLKCNMA1 | |
| SCHEMBL21884598 | 0.73 | CXCR1 (0.35) | P2RX1 | |
| Hydrochloric Acid SCHEMBL7942179 | 0.73 | MAPT (0.46) | KMT2ASCN5ASCN2AF2F10 | |
| SCHEMBL30954156 | 0.71 | DPP4 (0.54) | HSD17B1HSD17B2CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | HSD17B1 1039/4885HSD17B2 1221/4885CA1 2338/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | HSD17B1 4048/4885HSD17B2 4093/4885CA1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.